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OBJECTIVE—Activation of the nuclear hormone receptor
peroxisome proliferator–activated receptor (PPAR)-d has been
shown to improve insulin resistance, adiposity, and plasma HDL
levels. Several studies have reported that activation of PPARd is
atheroprotective; however, the role of PPARd in renal function
remains unclear. Here, we report the renoprotective effects of
PPARd activation in a model of streptozotocin-induced diabetic
nephropathy.
RESEARCH DESIGN AND METHODS—Eight-week-old male
C57BL/6 mice were divided into three groups: 1) nondiabetic
control mice, 2) diabetic mice, and 3) diabetic mice treated with
the PPARd agonist GW0742 (1 mg/kg/day). GW0742 was admin-
istered by gavage for 8 weeks after inducing diabetes.
RESULTS—GW0742 decreased urinary albumin excretion with-
out altering blood glucose levels. Macrophage inﬁltration, mesangial
matrix accumulation, and type IV collagen deposition were
substantially attenuated by GW0742. The gene expression of
inﬂammatory mediators in the kidney cortex, such as monocyte
chemoattractant protein-1 (MCP-1) and osteopontin (OPN), was
also suppressed. In vitro studies demonstrated that PPARd ac-
tivation increased the expression of anti-inﬂammatory corepressor
B-cell lymphoma-6, which subsequently suppressed MCP-1 and
OPN expression.
CONCLUSIONS—These ﬁndings uncover a previously unrecog-
nized mechanism for the renoprotective effects of PPARd ago-
nists and support the concept that PPARd agonists may offer
a novel therapeutic approach for the treatment of diabetic
nephropathy. Diabetes 60:960–968, 2011
T
he increasing prevalence of diabetic nephropa-
thy worldwide is a major societal issue because
of the enormous expense associated with kidney
replacement therapy (1). The pathogenesis of
diabetic nephropathy is complex and involves multiple
pathways that lead to kidney injury, including the polyol
pathway (2), protein kinase C (3), advanced glycation end
products (4), and transforming growth factor (TGF)-b (5).
In addition, inﬂammation is now recognized to play an
important role in the development of diabetic nephropathy
(6,7). In this condition, the accumulation of macrophages
and increased expression of cell adhesion molecules are
observed in renal biopsy specimens from patients with
diabetic nephropathy (8). We have demonstrated that in-
ﬂammation in diabetic nephropathy can be ameliorated by
inhibiting macrophage inﬁltration in intercellular adhesion
molecule-1 (ICAM-1) and macrophage scavenger receptor-
A (SR-A) knockout mice (9,10). Therefore, inﬂammation
could be a major therapeutic target of diabetic nephropathy.
There is an increasing body of evidence suggesting that
a subfamily of nuclear hormone receptor transcription fac-
tors, namely the peroxisome proliferator–activated recep-
tors (PPARs) (PPARg,P P A R a, and PPARd), may play
important roles in the pathogenesis of metabolic syn-
drome, obesity, and diabetes (11). PPARs are also implicated
in many renal pathophysiological conditions, including
diabetic nephropathy and glomerulosclerosis (12). Synthetic
PPARg and PPARa agonists, such as thiazolidinediones
and ﬁb r a t e s ,i m p r o v et h eg l y c e m i cc o n t r o li nt y p e2d i -
abetic patients and lower the serum triglyceride levels
in hyperlipidemic patients. In addition, we and other inves-
tigators have reported that PPARg and PPARa agonists are
also beneﬁcial in diabetic nephropathy (13–15). Although
atheroprotective effects of PPARd agonists have been
reported (16,17), there are no reports regarding the effects
of PPARd agonists on diabetic nephropathy.
The purpose of the current study was to investigate the
hypothesis that activation of PPARd prevents the develop-
ment of diabetic nephropathy by inhibiting inﬂammatory
processes, including chemokine/cytokine expression and
macrophage inﬁltration.
RESEARCH DESIGN AND METHODS
Experimental protocol. Male C57BL/6J mice were purchased from Charles
River (Yokohama, Japan). Eight-week-old mice were divided into three groups:
1) nondiabetic control mice (control; n = 6), 2) streptozotocin (STZ)–induced
diabetic mice (DM; n = 7), and 3) diabetic mice treated with PPARd agonist
GW0742 (DM+GW0742; n = 7). GW0742 mice were purchased from Sigma-
Aldrich (Tokyo, Japan). Diabetes was induced by peritoneal injection of 200
mg/kg STZ (Sigma-Aldrich) in citrate buffer (pH 4.5). Blood glucose was
measured by the glucose oxidase method at 3 and 7 days after STZ injection,
and only mice with blood glucose concentrations .16 mmol/L were used
in the study. Mice in the control group were injected with citrate buffer. The
DM+GW0742 group received 1 mg/kg/day of GW0742 by gavage for 8 weeks.
All mice had free access to standard diet and tap water. All procedures were
performed according to the Guidelines for Animal Experiments at Okayama
University Medical School, Japanese Government Animal Protection and
Management Law (No. 105), and Japanese Government Notiﬁcation on
Feeding and Safekeeping of Animals (No. 6). Mice were killed at 8 weeks after
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ORIGINAL ARTICLEFIG. 1. Time course of changes in UAE and PPARd mRNA and protein expression in the kidneys. A: The UAE increased progressively in the un-
treated diabetic (DM) group during the 8-week observation period after the induction of diabetes. GW0742 treatment (DM+GW0742) signiﬁcantly
reduced UAE at 8 weeks compared with the DM group. Control, nondiabetic control mice. Data are means 6 SE. *P < 0.01 for DM vs. DM+GW0742.
B: Renal PPARd mRNA expression was signiﬁcantly increased in the DM group compared with the control group. Data are means 6 SE. *P < 0.05.
C: Localization of renal PPARd protein expression by immunohistochemistry. PPARd protein expression was predominantly localized in the glo-
meruli of the DM and DM+GW0742 groups. Original magniﬁcation 3400. D: Localization of renal Bcl-6 protein expression by immunohisto-
chemistry. Bcl-6 protein was mainly expressed in the glomeruli of the control group, but its expression was suppressed in the DM group. The
expression of Bcl-6 recovered in the DM+GW0742 groups compared with the DM group. Original magniﬁcation 3400. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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formalin for periodic acid–methenamine silver (PAM) staining, and parts of
the remaining tissues were embedded in optimal cutting temperature com-
pound (Sakura Finetechnical, Tokyo, Japan) and frozen immediately in ace-
tone cooled on dry ice. Other tissues were snap-frozen in liquid nitrogen and
stored at 280°C.
Metabolic data. We measured body weight, blood pressure, hemoglobin A1c
(HbA1c), 24-h urinary albumin excretion (UAE), and creatinine clearance at 0,
4, and 8 weeks. Blood pressure was measured using the tail-cuff method
(Softron, Tokyo, Japan). HbA1c was measured using the high-pressure liquid
chromatography method, and serum creatinine was measured using the en-
zymatic method. Urine was collected for 24 h, with each mouse individually
housed in a metabolic cage and provided with food and water ad libitum.
Urinary albumin concentration was measured as previously described (9).
Creatinine was measured enzymatically, and creatinine clearance was calcu-
lated.
Light microscopy. PAM-stained sections were analyzed. To evaluate glo-
merular size, we examined 10 randomly selected glomeruli in the cortex per
animal under high magniﬁcation (3400) at 8 weeks after induction of diabetes.
The area of the glomerular tuft and the mesangial matrix index (MMI) were
measured using Lumina Vision software (Mitani Corporation, Tokyo, Japan).
MMI was deﬁned as the PAM-positive area in the tuft area, calculated using the
following formula: MMI = (PAM positive area)/(tuft area). The results are
expressed as means 6 SE (per mm
2 for tuft area; arbitrary units for MMI).
Immunoperoxidase staining. Immunoperoxidase staining was performed as
previously described (9). Brieﬂy, fresh frozen sections were cut to 4 mmt h i c k
using a cryostat. To evaluate macrophage inﬁltration, we applied a rat anti-
mouse monocyte/macrophage (F4/80) monoclonal antibody (Abcam, Tokyo,
Japan), followed by biotin-labeled goat antirat IgG antibody (Jackson Immu-
noresearch Laboratories, West Grove, PA). The avidin-biotin coupling reaction
was performed on sections using a Vectastain Elite kit (Vector Laboratories,
Burlingame, CA). We examined 10 glomeruli per animal and counted the
number of F4/80-positive cells. The mean number of positive cells per glo-
merulus and interstitial tissue (number per mm
2) were used for the estimation.
To evaluate PPARd and Bcl-6 expression, PPARd rabbit polyclonal antibody
(Afﬁnity BioReagents, Golden, CO) and Bcl-6 rabbit polyclonal antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) were applied, followed by biotin-
labeled donkey anti-rabbit IgG antibody (Jackson Immunoresearch Labora-
tories).
Immunoﬂuorescent staining. Immunoﬂuorescent staining was performed as
previously described (9). To clarify the differences in mesangial matrix pro-
teins, we used rabbit anti-type IV collagen antibody (Millipore, Temecula, CA),
followed by Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, Carlsbad, CA).
Fluorescence pictures were obtained using a ﬂuorescence microscope (BX51;
Olympus, Tokyo, Japan). The type IV collagen immunoﬂuorescence intensity
was quantiﬁed as previously described (9). Brieﬂy, using Lumina Vision soft-
ware (Mitani Corporation), the intensity of expression on the images was
calculated using the formula, x (density) 3 positive area (mm
2). The positive
area of type IV collagen in each glomerulus was estimated as the ratio to the
mean area of the glomerulus. Ten glomeruli per animal were evaluated.
Quantitative analysis of renal cortex gene expression. The RNA from the
renal cortex was isolated 8 weeks after treatment using an RNeasy Mini Kit
(Qiagen,Valencia,CA).Single-strand cDNAwassynthesizedfromtheextracted
RNAusing aRT-PCRkit(PerkinElmer,FosterCity,CA).ToevaluatethemRNA
expression of PPARd, CD14, CD11c, monocyte chemoattractant protein
(MCP)-1, chemokine CC motif receptor 2 (CCR2), TGF-b, tumor necrosis
factor (TNF)-a, osteopontin (OPN), and ICAM-1 in the renal cortex, quanti-
tative RT-PCR (qRT-PCR) was performed using StepOnePlus (Applied Bio-
systems, Tokyo, Japan) and FastStart SYBR Premix Ex Taq II (Takara Bio,
Otsu, Japan). The primers were purchased from Takara Bio. Each sample was
analyzed in triplicate and normalized for GAPDH mRNA expression.
Cell culture and treatment. RAW 264.7 murine macrophages were cultured
in Dulbecco’sm o d i ﬁed Eagle’s medium supplemented with 1,000 mg/L D-glucose,
10% FBS, 100 units/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L
L-glutamine. For ligand treatment, cells were serum-starved by culture in
0.5% FBS for 24 h. After pretreatment with GW0742 (10 mmol/L) for 24 h, the
cells were stimulated with 4,500 mg/L D-glucose (high glucose) for 24 h. In-
dividual experiments were repeated at least three times with different lots or
preparation of cells.
Quantitative analysis of gene expression in RAW macrophages. Total
RNA was prepared from cells using an RNeasy Mini Kit (Qiagen) as described
above. B-cell lymphoma-6 (Bcl-6), MCP-1, and OPN mRNA expression in RAW
macrophages was measured using qRT-PCR, as described above.
Immunoprecipitation and Western blotting. Bcl-6 and PPARd protein ex-
pression levels were determined by Western blotting. To examine the inter-
actions between PPARd and Bcl-6, the nuclear protein fraction was isolated
from RAW macrophages using a Nuclear Extract Kit (Active Motif, Carlsbad,
CA). The nuclear protein was immunoprecipitated with an anti-PPARd anti-
body (Afﬁnity BioReagents) for 1.5 h at 4°C. The nuclear protein–antibody
complex was then incubated with magnetized Protein G Dynabeads (Invi-
trogen) for 45 min at room temperature. After washing the beads, the bound
proteins were eluted and resolved by SDS-PAGE. Protein was transferred to
nitrocellulose membranes and blocked in 20 mmol/L Tris-HCl (pH 7.6) con-
taining 150 mmol/L NaCl, 0.1% Tween-20, and 5% (wt/vol) nonfat dried milk.
The blots were then incubated with anti-PPARd antibody (Afﬁnity BioRe-
agents) and anti–Bcl-6 antibody (Santa Cruz Biotechnology). The immuno-
blots were hybridized with anti-TATA binding protein antibody (Abcam) to
monitor equivalent loading in different lanes. All experiments were repeated at
least three times.
Statistical analysis. All values are means 6 SE. Statistically signiﬁcant dif-
ferences between groups were examined using one-way ANOVA followed by
Scheffé test. A P value ,0.05 was considered statistically signiﬁcant.
RESULTS
Metabolic data and time course of changes in UAE.
The UAE progressively increased in diabetic mice during
the study (Fig. 1A). However, GW0742 treatment signiﬁ-
cantly reduced the mean UAE (86.09 6 12.67 mg/day)
compared with the DM group at 8 weeks after inducing
diabetes (40.91 6 3.94 mg/day; P , 0.01). The other met-
abolic data are summarized in Table 1. Eight weeks after
inducing diabetes, there were no signiﬁcant differences in
systolic blood pressure between the three groups. HbA1c,
kidney weight, and relative kidney weight were signiﬁ-
cantly higher in the DM group than in the control group.
There was no signiﬁcant difference in HbA1c,k i d n e y
weight, and relative kidney weight between the DM and
the DM+GW0742 groups. Body weight was lower in both
the DM and the DM+GW0742 groups than in the control,
but was higher in the DM+GW0742 than in the DM group.
There were no signiﬁcant differences in creatinine clear-
ance or triglyceride levels between the three groups.
Renal PPARd and Bcl-6 expression. We found PPARd
mRNA and protein expression in the kidneys. At 8 weeks,
TABLE 1
Metabolic data at 8 weeks after inducing diabetes
Control DM DM+GW0742
n 67 7
Systolic blood pressure (mmHg) 97.8 6 7.9 111.8 6 4.4 110.1 6 3.5
HbA1c (%) 4.60 6 0.04 9.75 6 0.34* 8.81 6 0.62*
Body weight (g) 26.75 6 0.39 17.74 6 1.03* 20.70 6 0.41*†
Kidney weight (mg) 283.3 6 3.3 325.7 6 18.8‡ 295.7 6 6.1
Relative kidney weight (mg/g body wt) 11.82 6 0.27 18.85 6 1.87* 15.87 6 0.57
Creatinine clearance (mL/min) 249.0 6 34.8 349.5 6 40.4 348.1 6 44.7
Triglycerides (mg/dL) 23.6 6 2.0 27.9 6 7.3 21.5 6 4.8
Data are means 6 SE. *P , 0.01 vs. the control group. †P , 0.01 vs. the DM group. ‡P , 0.05 vs. the control group.
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the DM group than in the control group (0.71 6 0.18 vs.
0.24 6 0.07, respectively; P , 0.05) (Fig. 1B). However,
GW0742 treatment did not affect PPARd mRNA expres-
sion in renal tissues. Renal sections immunostained with
PPARd-speciﬁc antibodies revealed that PPARd protein
expression was predominantly localized in the glomeruli of
DM and DM+GW0742 groups and to a lesser extent in the
glomeruli of the control group (Fig. 1C). By contrast, the
anti-inﬂammatory corepressor Bcl-6 was mainly expressed
in the glomeruli of the control group, and its expression
was suppressed in the DM group. GW0742 treatment re-
covered the expression of Bcl-6 compared with the DM
group (Fig. 1D).
MMI and expression of type IV collagens in the
glomeruli. Representative glomeruli in PAM-stained sec-
tions are shown in Fig. 2A. Glomerular hypertrophy and
mesangial matrix expansion were observed in the DM group
at the end of the 8-week observation period. However, these
changes were ameliorated in the DM+GW0742 group com-
pared with DM group (MMI: 9.05 6 0.30 vs. 12.34 6 0.49%,
respectively; P , 0.001) (Fig. 2B). A similar trend was noted
for type IV collagen (Fig. 2C). The type IV collagen–positive
area in glomeruli was larger in the DM group than in
the control group. This area was markedly reduced in the
DM+GW0742 group compared with the DM group (9.57 6
0.18 vs. 12.33 6 0.49%, respectively; P , 0.001) (Fig. 2D).
Macrophage inﬁltration in the kidney. The number of
macrophages in the glomeruli was remarkably higher in
the DM group than in the control group. Interestingly,
macrophage inﬁltration into the glomeruli was signiﬁcantly
reduced in the DM+GW0742 group compared with the DM
group (1.80 6 0.08 vs. 2.69 6 0.05, respectively; P , 0.001)
(Fig. 3A and B). Similarly, macrophage inﬁltration into the
interstitium was increased in the DM group but was sup-
pressed in the DM+GW0742 group (13.79 6 0.53 vs. 7.75 6
0.77, respectively; P , 0.001) (Fig. 3A and C).
Macrophage and inﬂammatory gene expression in the
renal cortex. qRT-PCR analyses of kidney tissue demon-
strated that the expression of two macrophage marker
genes, CD14 and CD11c, was increased in the DM group
and that GW0742 treatment markedly reduced the ex-
pression of these genes (Fig. 4). CD14 is a marker for all
macrophages, and CD11c is speciﬁc for the M1 subtype
of macrophages. Similarly, the induction of diabetes in-
creased the renal expression of several proinﬂammatory
and proatherogenic genes, including MCP-1, TGF-b, OPN,
TNF-a, and ICAM-1. Although GW0742 decreased the ex-
pression of MCP-1, TGF-b, and OPN, it did not affect
TNF-a or ICAM-1 (Fig. 4). Of note, MCP-1, a key chemo-
kine involved in macrophage recruitment, plays a signiﬁ-
cant role in diabetic nephropathy because the absence of
MCP-1 signiﬁcantly reduces diabetic renal injury (18,19).
Similarly, OPN is also a critical inﬂammatory cytokine in-
volved in diabetic nephropathy (20,21). Collectively, these
data indicate that the PPARd agonist GW0742 inhibits
diabetes–induced macrophage recruitment and inﬂamma-
tory gene expression in the kidney.
PPARd and Bcl-6 expression in RAW macrophages.
PPARd has been demonstrated to directly affect the anti-
inﬂammatory transcriptional repressor Bcl-6. PPARd ago-
nists increase free Bcl-6 in macrophages, suppressing
MCP-1 transcription and decreasing macrophage inﬁltra-
tion (22). To investigate the regulation of renal inﬂamma-
tory pathways by diabetes and PPARd, and the roles of
Bcl-6 and PPARd in these processes, we performed in vitro
FIG. 2. PAM staining of kidney sections and the expression of type IV
collagen in the kidney. A: Representative glomeruli from control, DM, and
DM+GW0742 mice. Glomerular hypertrophy and mesangial matrix ex-
pansion were evident in the DM group. GW0742 suppressed the increase
in the MMI compared with the DM group. Original magniﬁcation 3400.
B: MMI in glomeruli. Data are means 6 SE. *P < 0.001. C: Type IV collagen
was signiﬁcantly increased in the DM group compared with the control
group and was decreased in the DM+GW0742 group compared with the
DM group. Original magniﬁcation 3400. D: Type IV collagen–positive area
in glomeruli. Data are means 6 SE. *P < 0.001. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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group and was suppressed in the DM+GW0742 group. Original magniﬁcation 3400. B: The number of intraglomerular macrophages. Data are means 6
SE. *P < 0.001. C: The number of macrophages in interstitium. Data are means 6 SE. *P < 0.001. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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that the high-glucose medium strongly inhibited Bcl-6
expression in RAW macrophages and that GW0742 treat-
ment signiﬁcantly attenuated this inhibition in macrophages
(Fig. 5A). We found that macrophages exposed to high
glucose had an increase in nuclear PPARd protein and that
pretreatment with GW0742 completely abolished this effect
(Fig. 5B). Western blot analyses of total and PPARd-bound
Bcl-6 in macrophage nuclear extracts revealed that high
glucose tended to suppress total Bcl-6 but markedly
increased PPARd–Bcl-6 complexes and that GW0742 pre-
treatment decreased PPARd–Bcl-6 binding (Fig. 5C). These
data indicate that high glucose can increase nuclear
PPARd–Bcl-6 binding, limiting the amount of free Bcl-6
available to repress the expression of inﬂammatory genes
normally suppressed by Bcl-6.
Inﬂammatory gene expression in RAW macrophages.
To further investigate the role of PPARd activation in in-
ﬂammatory processes, we examined the effects of GW0742
on inﬂammatory gene expression in macrophages. Consis-
tent with the changes in free Bcl-6, high glucose–stimulated
MCP-1 expression, which is regulated by Bcl-6, was at-
tenuated by GW0742 (Fig. 6A). The expression of OPN,
a macrophage chemokine, was also increased by expo-
sure to high glucose and suppressed by GW0742 (Fig. 6B).
DISCUSSION
In the current study, we demonstrated that the PPARd
agonist GW0742 ameliorated albuminuria, glomerular
mesangial expansion, and type IV collagen accumulation
without affecting blood glucose levels in STZ–induced
FIG. 4. PPARd activation suppresses diabetes–induced renal inﬂammation and macrophage inﬁltration. Quantitative RT-PCR analysis of the
expression of two macrophage markers (CD14 and CD11c) shows that GW0742 inhibited diabetes–induced macrophage inﬁltration into the kidney.
Similarly, GW0742 suppressed MCP-1, CCR-2, TGF-b, and OPN mRNA levels in the kidney. mRNA levels are normalized to GAPDH. Data are
means 6 SE. *P < 0.05.
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rophage inﬁltration in diabetic kidney and the expression
of inﬂammatory genes, including MCP-1, TGF-b,a n dOPN.
Furthermore, in vitro studies with RAW macrophages
revealed that high glucose suppressed the expression of
free Bcl-6, which was associated with increased expres-
sion of MCP-1 and OPN, and that GW0742 reversed these
effects. Our ﬁndings suggest that the activation of PPARd
FIG. 5. High glucose suppresses Bcl-6 expression in RAW macrophages. A: mRNA isolated from macrophages was analyzed by quantitative RT-PCR.
Bcl-6 expression was normalized to GAPDH. Data are means 6 SE. *P < 0.05. B: High glucose increases and GW0742 decreases macrophage PPARd
protein expression. PPARd expression was normalized to that of TBP. Data are means 6 SE. *P < 0.05. C: Bcl-6 protein expression and PPARd–Bcl-6
interaction in macrophages in response to high glucose and/or GW0742. The Bcl-6–PPARd interaction was analyzed by Western blotting of total and
PPARd-bound Bcl-6 in macrophage nuclear proteins after pull-down assays. Bcl-6 expression was normalized to that of TBP. Data are means 6 SE.
*P < 0.05.
FIG. 6. GW0742 suppresses MCP-1 (A) and OPN (B) mRNA expression in RAW macrophages. mRNA isolated from macrophages was analyzed by
quantitative RT-PCR. MCP-1 and OPN expression was normalized to GAPDH. Data are means 6 SE. *P < 0.05.
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prevents the development of nephropathy, independently
of blood glucose levels.
The nuclear receptor transcription factors PPARg,
PPARa, and PPARd are critical in regulating insulin sen-
sitivity, adipogenesis, lipid metabolism, and inﬂammation
(11). All three PPAR isoforms have been proposed as
therapeutic targets for the treatment of metabolic syndrome,
dyslipidemia, and diabetes (11). Several recent clinical
studies have provided evidence that thiazolidinedione,
PPARg agonists, and ﬁbrates, PPARa agonists, confer
a renoprotective effect in patients with type 2 diabetes
(23–25). Experimental studies have also shown beneﬁcial
effects of PPARg agonists on renal injury in type 1 and
type 2 diabetic animal models, and multiple mechanisms
seem to be involved (26,27). We previously demonstrated
that the PPARg agonist pioglitazone ameliorates diabetic
nephropathy by inhibiting cell cycle–dependent hypertro-
phy of podocytes by reducing Bcl-2 and p27Kip1 protein
levels (13) and by suppressing ICAM-1 expression and
macrophage inﬁltration by inhibiting nuclear factor-kB
activation in endothelial cells (14). PPARa agonists also
have renoprotective effects by reducing TGF-b and plas-
minogen activator inhibitor-1 expression in mesangial cells
(15). However, unlike PPARg and PPARa, little is known
about the therapeutic potential of PPARd agonists in di-
abetic nephropathy.
Many studies have proposed an important role of in-
ﬂammatory processes in the pathogenesis of diabetic ne-
phropathy (6,7). We previously reported macrophage
inﬁltration and increased expression of leukocyte adhe-
sion molecules in the kidneys of patients with diabetic
nephropathy in addition to mesangial matrix expansion
and interstitial ﬁbrosis (8). We have also described the
importance of ICAM-1–dependent inﬁltration of macro-
phages into the kidney in the pathogenesis of diabetic
nephropathy in a series of studies (9,28). Furthermore, we
have demonstrated that SR-A–deﬁcient mice are protected
from renal injury after induction of diabetes by inhibiting
macrophage migration into diabetic kidneys (10). Other
studies have reported that the chemokine MCP-1 plays an
important role in the pathogenesis of diabetic nephropathy
(29). The importance of MCP-1 in the early development of
diabetic nephropathy has been determined using animal
models incorporating genetically deﬁcient mice or thera-
peutic blockade of the MCP-1 receptor CCR2 (18,19,30). In
the current study, MCP-1 expression in the kidney was
increased in diabetic mice and suppressed by the admin-
istration of GW0742. PPARd activation has been suggested
to reduce MCP-1 and subsequently reduces the number of
recruited macrophages in diabetic glomeruli and inter-
stitium.
In this study, we found that diabetes signiﬁcantly in-
creased PPARd expression in the kidney, and that high
glucose increased PPARd expression in cultured RAW
macrophages. In contrast to our observations, Yu et al.
(31) reported a decrease in PPARd gene and protein ex-
pression in the myocardium of diabetic rats. On the other
hand, several investigators observed an increase in PPARd
expression in the lung (32), diaphragm (33), and aorta (16)
in diabetic animals. Taken together, these results suggest
that PPARd expression in the diabetic state differs be-
tween individual tissues and may depend on the balance
between the two major fuel utilization pathways (i.e.,
glucose vs. fatty acid metabolism and their cross-talk)
(33). The mechanisms by which high glucose increases the
expression of PPARd remain unclear, and further studies
are needed.
Unliganded PPARd, which binds to the anti-inﬂammatory
transcriptional repressor Bcl-6, reduces the amount of
free Bcl-6 available to suppress MCP-1 transcription,
thus increasing MCP-1 expression (22). We showed that
administration of the PPARd agonist GW0742 substantially
attenuated STZ–induced diabetic nephropathy without
altering the blood glucose level and increased the renal
expression of Bcl-6, which was associated with suppres-
sion of MCP-1 gene expression in the kidney. We have
searched for the PPRE in the promoter region of Bcl-6, but
have been unable to locate any PPRE sites. Thus, we
speculate that activation of PPARd may induce other
transcriptional factors, which induce Bcl-6 gene expres-
sion. Moreover, immunoprecipitation and Western blotting
revealed that high glucose increased the PPARd–Bcl-6
complex, reducing the amount of free Bcl-6 in cultured
macrophages. Activation of PPARd by GW0742 decreased
PPARd–Bcl-6 binding and increased the amount of free
Bcl-6, which consecutively decreased MCP-1 expression in
macrophages. Based on these in vivo and in vitro data, in-
hibition of MCP-1 expression by PPARd agonists is likely
mediated through increased expression of Bcl-6 (Fig. 7).
OPN acts as a chemokine and as a proinﬂammatory
cytokine (34). We previously demonstrated that OPN ex-
pression was increased in diabetic kidneys and suppressed
by SR-A deﬁciency (10). Other studies have shown that
OPN is expressed in renal resident cells and is regarded as
FIG. 7. Schematic diagram showing the mechanisms involved in the
renoprotective effects of PPARd in diabetic nephropathy. The anti-
inﬂammatory transcriptional repressor Bcl-6 represses the expression
of MCP-1. PPARd activation by GW0742 releases Bcl-6, which is associ-
ated with suppression of MCP-1, to attenuate macrophage inﬁltration,
inﬂammatory gene expression, and type IV collagen accumulation in the
kidney.
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thy (20,21). In this study, consistent with the changes in
MCP-1 expression, high glucose–induced OPN expression
in macrophages was attenuated by GW0742. Therefore,
inhibition of OPN expression by PPARd agonists may
contribute, at least in part, to the beneﬁcial renal effects of
PPARd agonists in diabetic nephropathy.
In conclusion, the data presented in this study indicate
that PPARd activation attenuates high glucose–induced
expression of MCP-1 and OPN by increasing the anti-
inﬂammatory repressor Bcl-6 in macrophages. The PPARd
agonist GW0742 shows renoprotective effects through its
anti-inﬂammatory activity by inhibiting MCP-1 expression
and macrophage inﬁltration in the diabetic kidney. Be-
cause MCP-1 is a key component in the inﬂammatory re-
sponse and the recruitment of monocytes/macrophages
into the diabetic kidney, inhibition of MCP-1 expression by
PPARd agonist could provide a potential therapeutic target
in human diabetic nephropathy.
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